Lung cancer working group report
Asia needs a guideline for non-small-cell lung cancer because of differences in medical care, medical care insurance, ethnic variation and drug approval lag within Asian countries and compared with Western countries. Due to ethnic differences, drug dosages are often higher in the USA than in Japan....
محفوظ في:
المؤلفون الرئيسيون: | Saijo N., Fukuoka M., Thongprasert S., Ichinose Y., Mitsudomi T., Mok T., Ohe Y., Park K., Wu Y. |
---|---|
التنسيق: | دورية |
منشور في: |
2017
|
الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77957280882&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/43250 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Lung cancer working group report
بواسطة: Nagahiro Saijo, وآخرون
منشور في: (2018) -
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
بواسطة: Wu Y.-L., وآخرون
منشور في: (2014) -
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
بواسطة: Fukuoka M., وآخرون
منشور في: (2017) -
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
بواسطة: Lee C., وآخرون
منشور في: (2017) -
Lung cancer and quality of life
بواسطة: Thongprasert S.
منشور في: (2014)